Jeffrey J. Barlow

Studies leading to the identification of ZD1839 (iressa™): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer

Andrew Barker, Keith H. Gibson, Walter Grundy et al. · Bioorganic & Medicinal Chemistry Letters · 2001 · 563 citations · Full text

Medicine, Oncology, Pharmacology +9

A novel series of potent and selective agonists at the opioid κ-receptor

Gerard Costello, Brain G. Main, Jeffrey J. Barlow et al. · European Journal of Pharmacology · 1988 · 70 citations

Medicine, Medicinal Chemistry, Pharmacology +11

Structure activity studies related to 2-(3,4-dichlorophenyl)-N-methyl-N-[2-(1-pyrrolidinyl)-1-substituted-ethyl]acetamides: a novel series of potent and selective .kappa.-opioid agonists

Jeffrey J. Barlow, Thomas P. Blackburn, Gerard Costello et al. · Journal of Medicinal Chemistry · 1991 · 44 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +17

.beta.-Adrenoceptor stimulant properties of amidoalkylamino-substituted 1-aryl-2-ethanols and 1-(aryloxy)-2-propanols

Jeffrey J. Barlow, Brian G. Main, H. M. Snow · Journal of Medicinal Chemistry · 1981 · 42 citations

Medicine, Medicinal Chemistry, Pharmacology +12

A quantitative method for the chromatographic separation of 17-oxo steroid sulphates from 17-oxo steroid glucuronides: with observations on the behaviour of conjugated corticosteroids on the same system

Jeffrey J. Barlow, A. E. Kellie · Biochemical Journal · 1959 · 28 citations · Full text

Life Sciences, Biochemistry, Pharmacology +12